SCHEMBL29985351

SCHEMBL29985351

CC(=O)c1cccc(C(F)(F)c2ccncc2)c1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 1/20 0.39
TYK2 P29597 3/20 0.37
HTT P42858 2/20 0.37
KDR P35968 4/20 0.36
FLT1 P17948 2/20 0.36
ABL1 P00519 1/20 0.36
EGFR P00533 1/20 0.36
CSF1R P07333 1/20 0.36
PDGFRB P09619 1/20 0.36
KIT P10721 1/20 0.36
FLT4 P35916 1/20 0.36
CTSS P25774 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
JAK2 O60674 2/20 0.35
JAK1 P23458 1/20 0.35
NOD2 Q9HC29 1/20 0.35
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34
TAS1R2 Q8TE23 1/20 0.34
PDK2 Q15119 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL377350 0.77 CTSS (0.51) GPBAR1CTSSTAS1R3TAS1R1TAS1R2
SCHEMBL29723227 0.77 CTSS (0.51) GPBAR1CTSSTAS1R3TAS1R1TAS1R2
SCHEMBL21132665 0.76 PDK2 (0.41) CTSSTAS1R3TAS1R1TAS1R2PDK2
SCHEMBL27190843 0.76 GABRA1 (0.36) GPBAR1USP2RAB9AP2RX7
SCHEMBL29092859 0.74 PTGS1 (0.40) CTSSRXFP1TAS1R3TAS1R1TAS1R2
SCHEMBL19726595 0.74 CA2 (0.43) CTSSTAS1R3TAS1R1TAS1R2PDK2
SCHEMBL25389241 0.73 RAB9A (0.34) TYK2EGFRUSP2RAB9A
SCHEMBL29985884 0.73 RAB9A (0.34) TYK2EGFRUSP2RAB9A
SCHEMBL29723392 0.73 PDK2 (0.41) CTSSTAS1R3TAS1R1TAS1R2PDK2
SCHEMBL23412079 0.73 PDK2 (0.41) CTSSTAS1R3TAS1R1TAS1R2PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240279221-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE SCHROEDINGER INC (US) 2024-08-22 US disclosed
EP-4346815-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE Schrödinger, Inc. (US) 2024-04-10 EP disclosed
CN-117715642-A Heterocyclic compounds and methods of use 薛定谔公司 2024-03-15 CN disclosed
WO-2022251497-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE SCHRÖDINGER, INC. (US) 2022-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279221-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE APC, RCC2, CDC37 GPBAR1 1001/4885TYK2 4002/4885HTT 2741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.